Submitted by comunicaciones on Mon, 11/18/2024 - 12:33
ECBE
ECBE USO DE ANTICOAGULANTES EN EL PACIENTE ADULTO
seccion ECBE
Referencias
Body
  1. Ilott I, Rick J, Patterson M, Turgoose C, Lacey A. What is protocol-based care? A concept analysis. J Nurs Manag. octubre de 2006;14(7):544-52.
  2. Gulwani S. Programming by examples: applications, algorithms, and ambiguity resolution. En 2017. p. 2-2.
  3. Harter K, Levine M, Henderson SO. Anticoagulation drug therapy: a review. West J Emerg Med. enero de 2015;16(1):11-7.
  4.  Kakkos SK, Gohel M, Baekgaard N, Bauersachs R, Bellmunt-Montoya S, Black SA, et al. Editor’s Choice - European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. Eur J Vasc Endovasc Surg. enero de 2021;61(1):9-82.
  5. Wijaya I, Andhika R, Huang I. The Use of Therapeutic-Dose Anticoagulation and Its Effect on Mortality in Patients With COVID-19: A Systematic Review. Clin Appl Thromb Hemost. 2020;26:1076029620960797.
  6.  Douketis JD, Spyropoulos AC. Perioperative Management of Anticoagulant and Antiplatelet Therapy. NEJM Evid. junio de 2023;2(6):EVIDra2200322.
  7.  Santagostino E, Lentz SR, Misgav M, Brand B, Chowdary P, Savic A, et al. Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardianTM clinical trials. Haemophilia. enero de 2015;21(1):34-40.
  8.  Douketis JD, Spyropoulos AC, Murad MH, Arcelus JI, Dager WE, Dunn AS, et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest. noviembre de 2022;162(5):e207-43.
  9. Jun GT, Ward J, Morris Z, Clarkson J. Health care process modelling: which method when? Int J Qual Health Care. junio de 2009;21(3):214-24.
  10. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 29 de marzo de 2021;372:n71.
  11. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 21 de enero de 2020;41(4):543-603.
  12. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. noviembre de 2016;50(5):e1-88.
  13.  Alquwaizani M, Buckley L, Adams C, Fanikos J. Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. Curr Emerg Hosp Med Rep. 2013;1(2):83-97.
  14. Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, et al. 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 4 de agosto de 2020;76(5):594-622.
  15. Barrera LM, Perel P, Ker K, Cirocchi R, Farinella E, Morales Uribe CH. Thromboprophylaxis for trauma patients. Cochrane Database Syst Rev. 28 de marzo de 2013;(3):CD008303.
  16. Abraham NS, Barkun AN, Sauer BG, Douketis J, Laine L, Noseworthy PA, et al. American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period. Am J Gastroenterol. 1 de abril de 2022;117(4):542-58.
  17. Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Can J Cardiol. diciembre de 2020;36(12):1847-948.
  18. 18. Vázquez FJ, Lifschitz E, Watman R, Vilaseca AB, Rodríguez VE, Cruciani AJ, et al. [Venous thromboembolic prophylaxis. Guidelines for adults in Argentina]. Medicina (B Aires). 2013;73 Suppl 2:1-26.
  19. Vazquez FJ, Korin J, Baldessari EM, Capparelli FJ, Gutierrez P, Pale C, et al. [Updated recommendations for venous thromboembolic prophylaxis in Argentina]. Medicina (B Aires). 2020;80(1):69-80.
  20. Mani H, Lindhoff-Last E. New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Des Devel Ther. 17 de junio de 2014;8:789-98.
  21. Dreijer AR, Diepstraten J, Brouwer R, Croles FN, Kragten E, Leebeek FWG, et al. Risk of bleeding in hospitalized patients on anticoagulant therapy: Prevalence and potential risk factors. Eur J Intern Med. abril de 2019;62:17-23.
  22. Dhakal P, Rayamajhi S, Verma V, Gundabolu K, Bhatt VR. Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants. Clin Appl Thromb Hemost. julio de 2017;23(5):410-5.
  23. Tiryaki F, Nutescu EA, Hennenfent JA, Karageanes AM, Koesterer LJ, Lambert BL, et al. Anticoagulation therapy for hospitalized patients: patterns of use, compliance with national guidelines, and performance on quality measures. Am J Health Syst Pharm. 1 de julio de 2011;68(13):1239-44.
  24. Brouwers MC, Kerkvliet K, Spithoff K, AGREE Next Steps Consortium. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines. BMJ. 8 de marzo de 2016;352:i1152.
  25. Schünemann HJ, Cushman M, Burnett AE, Kahn SR, Beyer-Westendorf J, Spencer FA, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 27 de noviembre de 2018;2(22):3198-225.
  26. Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 23 de febrero de 2021;5(4):927-74.
  27. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 9 de julio de 2019;140(2):e125-51.
  28. Decousus H, Tapson VF, Bergmann JF, Chong BH, Froehlich JB, Kakkar AK, et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest. enero de 2011;139(1):69-79.
  29. Thachil J, Carrier M, Lisman T. Anticoagulation in thrombocytopenic patients - Time to rethink? J Thromb Haemost. septiembre de 2022;20(9):1951-6.
  30. Bartlett MA, Mauck KF, Stephenson CR, Ganesh R, Daniels PR. Perioperative Venous Thromboembolism Prophylaxis. Mayo Clin Proc. diciembre de 2020;95(12):2775-98.
  31. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. abril de 2024;105(4S):S117-314.
  32. Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. julio de 2022;23(7):e334-47.
  33. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. marzo de 2017;43(3):304-77.
  34. Falanga A, Ay C, Di Nisio M, Gerotziafas G, Jara-Palomares L, Langer F, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol. mayo de 2023;34(5):452-67.
  35. Sebaaly J, Covert K. Enoxaparin Dosing at Extremes of Weight: Literature Review and Dosing Recommendations. Ann Pharmacother. septiembre de 2018;52(9):898-909.
  36. Abildgaard A, Madsen SA, Hvas AM. Dosage of Anticoagulants in Obesity: Recommendations Based on a Systematic Review. Semin Thromb Hemost. noviembre de 2020;46(8):932-69.
  37. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 15 de mayo de 2008;111(10):4902-7.
  38. Dutia M, White RH, Wun T. Risk assessment models for cancer-associated venous thromboembolism. Cancer. 15 de julio de 2012;118(14):3468-76.
  39. Candeloro M, Guman NAM, Kraaijpoel N, Di Nisio M. Risk Assessment Models for Thrombosis and Anticoagulant-Related Bleeding in Ambulatory Cancer Patients. Semin Thromb Hemost. noviembre de 2021;47(8):972-81.
  40. Tideman PA, Tirimacco R, St John A, Roberts GW. How to manage warfarin therapy. Aust Prescr. abril de 2015;38(2):44-8.
  41. Shendre A, Beasley TM, Brown TM, Hill CE, Arnett DK, Limdi NA. Influence of Regular Physical Activity on Warfarin Dose and Risk of Hemorrhagic Complications. Pharmacotherapy. junio de 2014;34(6):545-54.
  42. Frey PM, Méan M, Limacher A, Jaeger K, Beer HJ, Frauchiger B, et al. Physical activity and risk of bleeding in elderly patients taking anticoagulants. J Thromb Haemost. febrero de 2015;13(2):197-205.
  43. Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2 de enero de 2024;149(1):e1-156.
  44. Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. enero de 2016;41(1):206-32.
  45. Smythe MA, Priziola J, Dobesh PP, Wirth D, Cuker A, Wittkowsky AK. Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis. enero de 2016;41(1):165-86.
  46. Witt DM, Clark NP, Kaatz S, Schnurr T, Ansell JE. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombolysis. enero de 2016;41(1):187-205.
  47. Bitar ZI, Maadarani OS, Mohsen MJ, Alkazemi NU. Bariatric Surgery can Lower the Efficacy of DOACs. Eur J Case Rep Intern Med. 29 de septiembre de 2020;7(12):001954.
  48. Tseng E, Crowther MA, Hillis CM. Bridging anticoagulation for interruption of warfarin in a patient with atrial fibrillation. CMAJ. 15 de marzo de 2016;188(5):361-2.
  49. Wein T, Lindsay MP, Côté R, Foley N, Berlingieri J, Bhogal S, et al. Canadian stroke best practice recommendations: Secondary prevention of stroke, sixth edition practice guidelines, update 2017. Int J Stroke. junio de 2018;13(4):420-43.
  50. Sikes L, Charles K, Antigua A, Patel R, Imboywa S, Cherian P. Anti-Factor Xa Level Monitoring for Enoxaparin Prophylaxis and Treatment in High-Risk Patient Groups. HCA Healthc J Med. 4(2):105-9.
  51. Wei MY, Ward SM. The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis. Hematol Rep. 23 de noviembre de 2015;7(4):5844.
  52. Williams-Norwood T, Caswell M, Milner B, Vescera JC, Prymicz K, Ciszak AG, et al. Design and Implementation of an Anti-Factor Xa Heparin Monitoring Protocol. AACN Adv Crit Care. 15 de junio de 2020;31(2):129-37.
  53. Testa S, Paoletti O, Giorgi-Pierfranceschi M, Pan A. Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients. Intern Emerg Med. 2020;15(5):751-3.
  54. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. abril de 2006;4(4):759-65.
  55. Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 27 de noviembre de 2018;2(22):3360-92.
  56. Witt DM, Nieuwlaat R, Clark NP, Ansell J, Holbrook A, Skov J, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 27 de noviembre de 2018;2(22):3257-91.
  57. Hylek EM, Chang YC, Skates SJ, Hughes RA, Singer DE. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med. 12 de junio de 2000;160(11):1612-7.